Plain-English translation of NCT05503797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new cancer medication called in people whose tumors have specific genetic changes (called BRAF alterations). The study includes several groups of patients with different types of cancer—including brain tumors, thyroid cancer, ovarian cancer, and other rare cancers. Researchers want to see whether this medication can slow or shrink these tumors and understand how safe it is.
Many cancers with BRAF genetic changes don't respond well to standard treatments, or patients run out of options when existing therapies stop working. This medication is designed to target these specific genetic changes, offering hope for people with cancers that are hard to treat with available options.
You likely qualify if…
You likely don't qualify if…
You would take the medication continuously in 3-week treatment cycles, taken by mouth. You'll have regular visits with the research team to monitor how you're doing, check for side effects, and get scans to see if the tumor is responding. You'll continue treatment as long as the medication is helping and you're tolerating it well, or until your doctor decides it's time to stop. The study includes about 254 participants total across different cancer types.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States